GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Revenue per Share

ValiRx (LSE:VAL) Revenue per Share : £0.00 (TTM As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Revenue per Share?

ValiRx's revenue per share for the six months ended in Jun. 2023 was £0.00. ValiRx's revenue per share for the trailing twelve months (TTM) ended in Jun. 2023 was £0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for ValiRx's Revenue per Share or its related term are showing as below:

During the past 13 years, ValiRx's highest 3-Year average Revenue Per Share Growth Rate was 38.10% per year. The lowest was -60.20% per year. And the median was -37.35% per year.

LSE:VAL's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.4
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

ValiRx Revenue per Share Historical Data

The historical data trend for ValiRx's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Revenue per Share Chart

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ValiRx's Revenue per Share

For the Biotechnology subindustry, ValiRx's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ValiRx's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's PS Ratio distribution charts can be found below:

* The bar in red indicates where ValiRx's PS Ratio falls into.



ValiRx Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

ValiRx's Revenue Per Share for the fiscal year that ended in Dec. 2022 is calculated as

Revenue Per Share (A: Dec. 2022 )=Revenue (A: Dec. 2022 )/Shares Outstanding (Diluted Average) (A: Dec. 2022 )
=0/77.302
=0.00

ValiRx's Revenue Per Share for the quarter that ended in Jun. 2023 is calculated as

Revenue Per Share (Q: Jun. 2023 )=Revenue (Q: Jun. 2023 )/Shares Outstanding (Diluted Average) (Q: Jun. 2023 )
=0/100.808
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ValiRx  (LSE:VAL) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


ValiRx Revenue per Share Related Terms

Thank you for viewing the detailed overview of ValiRx's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx (LSE:VAL) Business Description

Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.

ValiRx (LSE:VAL) Headlines

From GuruFocus

Valaris to Present at the BofA Securities Global Energy Conference

By Business Wire Business Wire 11-14-2022

Valaris Issues Fleet Status Report

By Business Wire 11-01-2023

Valaris Provides Fleet Status Report

By Business Wire Business Wire 05-02-2023

Valaris Reports Second Quarter 2023 Results

By Business Wire 08-02-2023

Valaris Announces Drillship Contract Award

By Business Wire 07-31-2023

Valaris Announces Contract Awards and Fleet Status Updates

By Business Wire Business Wire 12-16-2022